CoChat

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial

Open access

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

PURPOSE: The efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily (OD) compared with insulin glargine U100 (IGlar) OD over 52 weeks in insulin-naïve adults with type 2 diabetes mellitus (T2DM) was investigated. METHODS: In this open-label, parallel-group treat-to-target trial, participants were randomized (1:1) to receive IDegAsp OD (breakfast, n = 266) or IGlar OD (as per label, n = 264). Participants then entered a 26-week extension phase (IDegAsp OD, n = 192; IGlar OD, n = 221). The primary endpoint was change from baseline to Week 26 in HbA1c. RESULTS: After 26 and 52 weeks, mean HbA1c decreased to similar levels in both groups. After 52 weeks, the mean estimated treatment difference was -0.08% (-0.26, 0.09 95%CI), confirming the non-inferiority of IDegAsp OD versus IGlar OD evaluated at Week 26. After 52 weeks, there was a similar reduction in mean fasting plasma glucose in both treatment groups. The rate of confirmed hypoglycemic episodes was 86% higher (p < 0.0001) whereas the rate of nocturnal hypoglycemia was 75% lower (p < 0.0001) for IDegAsp versus IGlar. CONCLUSION: Nocturnal-confirmed hypoglycemia was higher with IGlar whereas overall and diurnal hypoglycemia were higher with IDegAsp dosed at breakfast. These results highlight the importance of administration of IDegAsp with the main meal of the day, tailored to the individual patient's needs. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01045707 [core]) and NCT01169766 [ext].

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0163350

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Study flow diagram; core and extension study phases. IDegIAsp, insulin degludec/insulin aspart; IGlar, insulin glargine (U100); OD, once daily; n, number of participants.
Fig 1 Study flow diagram; core and extension study phases. IDegIAsp, insulin degludec/insulin aspart; IGlar, insulin glargine (U100); OD, once daily; n, number of participants.CC BY · PubMed Central
Fig 2 (A) Mean HbA1c over time to 52 weeks, (B) mean fasting plasma glucose (FPG) over time to 52 weeks, (C) mean self-measured blood glucose profile at baseline, Week 0 and Week 52, and (D) mean prandial increment at breakfast, lunch, main evening meal and overall at 52 weeks. (A) and (B): Data are mean ± SEM in the full analysis set. Missing data were imputed using last observation carried forward. *Calculated, not measured. Treatment differences are derived from a least square means-based model. (C) and (D): Full analysis set. Missing data were imputed using last observation carried forward. Prandial increment is the difference between SMPG values after meal (90 min) and before meal. Comparisons: estimates adjusted for multiple covariates. *Indicate statistically significant difference at Week 52 before breakfast (p < 0.05), and at 04.00 h and at breakfast the following day (p < 0.0001). **Before breakfast: estimated treatment difference (ETD) 0.81 mmol/L; 95% CI 0.46, 1.17. †At 4.00 h: ETD 0.53 mmol/L; 95% CI 0.10, 0.95. ‡Before breakfast the following morning: ETD 0.89 mmol/L; 95% CI 0.56, 1.23. IDegIAsp, insulin degludec/insulin aspart; HbA1c, glycosylated hemoglobin; IGlar, insulin glargine (U100); OD, once daily; SEM, standard error of the mean; SMPG, self-measured plasma glucose.
Fig 2 (A) Mean HbA1c over time to 52 weeks, (B) mean fasting plasma glucose (FPG) over time to 52 weeks, (C) mean self-measured blood glucose profile at baseline, Week 0 and Week 52, and (D) mean prandial increment at breakfast, lunch, main evening meal and overall at 52 weeks. (A) and (B): Data are mean ± SEM in the full analysis set. Missing data were imputed using last observation carried forward. *Calculated, not measured. Treatment differences are derived from a least square means-based model. (C) and (D): Full analysis set. Missing data were imputed using last observation carried forward. Prandial increment is the difference between SMPG values after meal (90 min) and before meal. Comparisons: estimates adjusted for multiple covariates. *Indicate statistically significant difference at Week 52 before breakfast (p < 0.05), and at 04.00 h and at breakfast the following day (p < 0.0001). **Before breakfast: estimated treatment difference (ETD) 0.81 mmol/L; 95% CI 0.46, 1.17. †At 4.00 h: ETD 0.53 mmol/L; 95% CI 0.10, 0.95. ‡Before breakfast the following morning: ETD 0.89 mmol/L; 95% CI 0.56, 1.23. IDegIAsp, insulin degludec/insulin aspart; HbA1c, glycosylated hemoglobin; IGlar, insulin glargine (U100); OD, once daily; SEM, standard error of the mean; SMPG, self-measured plasma glucose.CC BY · PubMed Central
Fig 3 (A) Confirmed and (B) nocturnal confirmed hypoglycemic events over 52 weeks. Safety analysis set. Comparisons: estimates adjusted for multiple covariates. IDegIAsp, insulin degludec/insulin aspart; IGlar, insulin glargine (U100); OD, once daily.
Fig 3 (A) Confirmed and (B) nocturnal confirmed hypoglycemic events over 52 weeks. Safety analysis set. Comparisons: estimates adjusted for multiple covariates. IDegIAsp, insulin degludec/insulin aspart; IGlar, insulin glargine (U100); OD, once daily.CC BY · PubMed Central
Fig 4 Cumulative frequency of hypoglycemia. * (A) Core phase and (B) extension phase. *Safety analysis set.IDegIAsp, insulin degludec/insulin aspart; IGlar, insulin glargine (U100); OD, once daily.
Fig 4 Cumulative frequency of hypoglycemia. * (A) Core phase and (B) extension phase. *Safety analysis set.IDegIAsp, insulin degludec/insulin aspart; IGlar, insulin glargine (U100); OD, once daily.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 1

  1. A Vaag, 2013, Lower rates of overall, nocturnal and severe hypoglycaemia during maintenance treatment with IDegAsp vs biphasic insulin aspart 30 in patients with type 2 diabetes mellitus: a meta-analysis, Diabetologia, 56, S83

Cited by

See all 38

Metadata

Authors
Kumar, A., Franek, E., Wise, J., Niemeyer, M., Mersebach, H., & Simó, R.
Affiliations
  • Diabetes Care and Research Foundation (IN)
  • Central Clinical Hospital (PL)
  • Tulane University (US)
  • Novo Nordisk (Germany) (DE)
  • Universitat Autònoma de Barcelona (ES)
Corresponding author
Kumar, Ajay
Venue
PLOS ONE
Published
2016-10-19
Volume
11
Issue
10
Pages
e0163350
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2532403559
Cited by
38
References
27
Citations by year
2025: 4 · 2024: 2 · 2023: 1 · 2022: 7 · 2021: 8 · 2020: 5 · 2019: 5 · 2018: 3 · 2017: 2
FWCI
3.35
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
Novo Nordisk A/S
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
IDegAsp, insulin glargine U100, type 2 diabetes, insulin-naive patients, basal insulin, HbA1c, glycemic control, hypoglycemia, nocturnal hypoglycemia, fasting blood glucose, meal timing, insulin administration
MeSH terms
Insulin Glargine, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Drug Combinations, Female, Humans, Male, Middle Aged, Safety, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1371/journal.pone.0163350
The paper
Kumar, A., Franek, E., Wise, J., Niemeyer, M., Mersebach, H., & Simó, R. (2016). Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0163350

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.